The success of renal transplantation may be counterbalanced by serious adverse medical events. The effect of immunosuppression on the incidence of de novo neoplasms among kidney recipients should be monitored continuously. Using data from the Scientific Registry of Transplant Recipients, we studied the association of induction therapy by immunosuppression with antilymphocyte antibodies, with the development of de novo neoplasms. The study population included more than 41 000 recipients who received a cadaveric first kidney transplant after December 31, 1995, and were followed through February 28, 2002.
Introduction
The incidence of malignancy is significantly higher for organ transplant recipients than for the general population that has not undergone transplantation. For instance, the incidence of post-transplant lymphoproliferative disorder (PTLD) among kidney transplant recipients is approximately 1%, which confers a risk of lymphoma approximately 20-fold greater than that seen in the general population (1) . Several cross-sectional studies (2-6) suggest a close relationship between immunosuppression and incidence rates of de novo solid tumors and PTLD among recipients of kidneys and other solid organ transplants.
As a consequence of immunosuppressive therapy to prevent transplant rejection, a transplant recipient's immune surveillance mechanism for tumor cells is likely to be compromised. In fact, recipients of organ transplants are slightly more vulnerable to the development of uncommon tumors and also have a higher incidence of some more common tumors, such as skin cancer (2%) (6, 7) . Skin cancer (basal and squamous cell types) is the most common tumor in both the transplant and normal population, but transplant recipients are threefold more likely to develop it (8) .
Most PTLD is thought to be caused by transformations of lymphoid tissue frequently resulting from uncontrolled Epstein-Barr virus (EBV) infection or reactivation of latent EBV infection. It afflicts many recipients of solid organ transplants (9) (10) (11) . Previous studies have shown that transplant recipients at increased risk for PTLD include children with primary EBV infection (12) and recipients who have been heavily immunosuppressed (11, 13, 14) . It has been shown that kidney recipients who receive less immunosuppression have a lower risk of developing PTLD (15) . Such patients include recipients of a living-related donor kidney, as well as cadaveric kidney transplant recipients who have never had a rejection episode and thus have not been exposed to the most intensive post-transplant immunosuppression therapy.
Patients with post-transplant malignancies have higher rates of mortality. Among all US patients with functioning kidney transplants received between 1994 and 1996, the total death rate was approximately 25.8 per 1000 patient years. Moreover, the death rate from malignant diseases was 1.9 per 1000 patient years, which represents approximately 7% (1.9/25.8) of the total death rate (16) .
Most of the above-cited studies investigated the amount and duration of administered immunosuppression and rates of post-transplant malignancy. In this study we examine the incidence of de novo tumors and PTLD in kidney recipients exposed to specific immunosuppressive agents. We focus specifically on the use of antilymphocyte preparations as induction therapy at time of transplantation, as the use of these agents has been associated with an increase in the severity and frequency of infection compared with noninduction immunosuppressive regimens (17, 18) .
Data and Methods
The database of the Scientific Registry of Transplant Recipients (SRTR) includes extensive data for all solid organ transplant recipients in the US (19). Major components of the SRTR data are collected by the Organ Procurement and Transplantation Network (OPTN); the database also includes information from other national sources (20) . Transplant centers report known post-transplant malignancies to the OPTN at 6 months and at each anniversary following transplantation.
On the OPTN data collection forms, and therefore in the SRTR database, de novo tumors are classified by site: bladder; breast; colorectal; liver; prostate; renal carcinoma; skin; lung; stomach; vulva, perineum or penis, and scrotum; other cancer; and primary unknown. Post-transplant lymphoproliferative disorder is classified as polymorphic hyperplasia, monomorphic or polymorphic PTLD (lymphoma), multiple myeloma, plasmacytoma, or Hodgkin's disease.
For this study, we defined induction therapy as immunosuppression during the initial transplant hospitalization with one of the following agents: equine antithymocyte globulin ( Additional analyses were performed including separate categories for equine antithymocyte globulin (ATG), rabbit antithymocyte globulin, muromonab-CD3, daclimuzab, and basiliximab in the model. The remaining medications for induction therapy, T10B9 (Medimmune) (<0.1%) and NRATG/NRATS (0.6%), were grouped together in a separate category.
Further analyses were also performed to investigate the effect of different maintenance therapies on the risk of de novo tumors and PTLD, for patients with and without induction therapy. Two calcineurin inhibitors were chosen for comparison: tacrolimus and cyclosporine. Other comparisons were also made between two antimetabolites: azathioprine and mycophenolate mofetil (MMF). Both comparisons were adjusted for all the patient factors included in the main model as well as for the effects of both antimetabolites and calcineurine inhibitors.
Results
Our data showed that 45% of patients received induction therapy at the time of transplantation. Results from a logistic model for identifying groups of patients more likely to receive induction therapy showed that pediatric (<18 years of age) recipients were more likely to receive induction therapy than recipients older than 50 years of age (odds ratio = 1.42, p < 0.001); all other age groups had a likelihood similar to that of patients older than 50 years. Increased odds of receiving induction therapy were also observed for females compared with males and for a more recent year of transplantation, while decreased odds were observed for Whites and Asians compared with Blacks, and for recipients with positive Hepatitis B core antibody. Table 2 shows the average length of follow up (in years) in a cross-tabulation of induction therapy by de novo tumors and PTLD. Although the follow-up period for patients with de novo tumors was 6 months longer in our analysis, the markedly shorter average length of follow up for patients with PTLD compared with that for patients with de novo tumors, as seen in Table 2 , indicates earlier incidence of PTLD. Mean or percent values of the factors examined in the analyses are shown in the second column of Tables 3 and 4 . Figures 1 and 2 show the estimated percentages, obtained from the unadjusted Kaplan-Meier survival curves, of patients with de novo tumors and PTLD, respectively, stratified by whether or not the patient received induction therapy. The curves for de novo tumors (Figure 1 ) show similar percentages of patients developing tumors with and without induction therapy. These percentages were compared using a log-rank test that resulted in a p-value of 0.31. In contrast, the percentage of patients with PTLD ( Figure 2 ) was significantly higher for those with induction therapy (p = 0.005). During the first 6 months following transplant, the difference between the two groups' rates was small. The apparent increase suggested by the undulating patterns in Figures 1 and 2 at each anniversary is likely a reflection of imprecise reporting of the date of first malignancy diagnosis during each annual follow-up visit.
The results of fitting the two multivariate Cox models to the data are shown in Tables 3 and 4. Table 3 provides results of a model for time to the development of de novo tumors (starting at 6 months post-transplant), and Table 4 Induction therapy was significantly associated with higher risk (RR = 1.78, p < 0.001) of developing PTLD (Table 4) , but not of developing de novo tumors (RR = 1.07, p = 0.42) ( Table 3 ). The RR of PTLD indicates that the risk of developing PTLD is approximately 1.8-fold higher among recipients of induction therapy. Greater risk of PTLD was also significantly associated with younger recipient age (RR = 0.86 per 10 years older), males compared with females (RR = 1.43), non-Hispanic ethnicity compared The effect of including indicators for the specific medications for induction therapy in the model for de novo tumors was not significant (p = 0.19). However, Table 5 shows a trend (RR = 1.24) of borderline significance (p = 0.08) towards a higher risk of de novo tumors for recipients receiving induction therapy with ATG compared with those who received no antilymphocyte induction. No significant differences were found among the specific medications for induction therapy in the model for de novo tumors (p = 0.18).
The effect of including indicators for the specific medications for induction therapy in the model for PTLD was highly significant (p = 0.010). Table 6 shows that, except for ATG (RR = 1.50, p = 0.10), the risk of developing PTLD was significantly higher for recipients that received any of the anti- The effect of receiving maintenance with tacrolimus compared with that of maintenance with cyclosporine on the risk of de novo tumors and PTLD was analyzed, and comparisons between these effects were made for recipients with and without induction therapy. Of all kidney recipients who received induction therapy (45%), 55.7% were reported to have received maintenance with cyclosporine, 34.3% received maintenance with tacrolimus, and 6.6% received maintenance with neither drug. Of all kidney recipients not receiving induction therapy (55%), 55.7% received maintenance with cyclosporine, 27.2% received maintenance with tacrolimus, and 11.0% received maintenance with neither drug. For the purpose of making reliable comparisons, the remaining 3.4% of patients with induction and 6.1% of patients without induction who were reported to have received maintenance with both cyclosporine and tacrolimus during the same observation period were not included in these additional analyses.
The results for these analyses by maintenance therapy showed that among kidney recipients who received induction therapy, the risk of developing de novo tumors was nonsignificantly higher for those who received maintenance tacrolimus vs. cyclosporine (RR = 1.16, p = 0.38). However, among recipients not receiving induction, the risk of developing de novo tumors was significantly lower (RR = 0.70, p = 0.020) for those who received maintenance tacrolimus compared with those receiving maintenance cyclosporine. This observation for maintenance tacrolimus vs. cyclosporine was significantly different for those receiving induction than for those not receiving induction (p = 0.024).
Similar comparisons showed that among recipients who received induction therapy, the risk of developing PTLD was nonsignificantly higher (RR = 1.12, p = 0.64) for those who received maintenance tacrolimus vs. cyclosporine. Among recipients not receiving induction, the risk of developing PTLD was significantly higher for those who received maintenance tacrolimus vs. cyclosporine (RR = 2.03, p = 0.008). This difference in PTLD risk for recipients with and without induction was of borderline significance only (p = 0.091).
Comparisons were also made between the effects of receiving maintenance with azathioprine and maintenance with MMF on the risk of developing de novo tumors and PTLD. Of all kidney recipients who received induction therapy, 71.8% received maintenance with MMF, 13.2% received maintenance with azathioprine, and 10.3% received maintenance with neither drug. Of all kidney recipients not receiving induction therapy, 60.6% received maintenance with MMF, 12.0% received maintenance with azathioprine, and 23.1% received maintenance with neither drug. The remaining 4.7% of patients with induction and 4.3% of patients without induction that were reported to have received maintenance with both azathioprine and MMF during the same observation period were excluded from these analyses.
The risk of developing de novo tumors and that for PTLD were not significantly modified by maintenance azathioprine vs. MMF whether or not the patient received induction therapy.
Discussion
Post-transplant malignancies are receiving increased attention as important complications following transplantation. By studying a large cohort of cadaveric first kidney transplant recipients, we found that induction therapy was associated with an increased risk of PTLD but not of de novo tumors. The negative finding for de novo tumors may be the result of the relatively short length of follow up for more recently transplanted patients, as antilymphocyte antibody induction therapy has been found to be associated with higher risk for late malignancy-related death (18) .
In seeking to study the effects of specific immunosuppressants on the incidence of de novo tumors and PTLD, the use of the SRTR database offered a number of advantages. The database is large, comprehensive, and includes national data. In addition, patients were followed for an average time of approximately 4 years after transplantation, allowing a sufficient amount of time to detect malignancy cases. It should be emphasized, however, that there might be underreporting of malignancy cases in these data. Thus, ascertainment of malignancy might not be complete during follow up. The SRTR is in the process of conducting linkage studies using several sources of information in order to validate the data captured in the SRTR database (20) . Preliminary data suggest underreporting of malignancies; the results of the present study assume that such underreporting does not bias our findings. More recent years in the present study appear to show an improved ascertainment, as suggested by the increased relative risk by year of transplantation (Tables 3 and 4 ). With more complete ascertainment, additional factors may be identified as significantly associated with PTLD or de novo solid tumors.
Several prior studies have focused on the relationship between post-transplant malignancy and the administered dose or duration of immunosuppressive therapy, factors that may contribute to the risk of post-transplant malignancy (6, 7, 22) . Information on dose and duration of therapy is not complete in the SRTR database. Instead, we investigated the relationship between post-transplant malignancy and a list of selected immunosuppressive agents used for induction therapy, comparing malignancy rates to those observed in the absence of antilymphocyte induction treatment. Our analyses showed statistical evidence that the risk of developing PTLD (RR = 1.78) among cadaveric first kidney transplant recipients is significantly associated with induction therapy (p < 0.001). There was also a nonsignificant trend (p = 0.42) toward a greater risk of developing de novo tumors (RR = 1.07) among recipients who were treated with induction agents. Our analyses also showed that in the presence of induction therapy, the choice of maintenance tacrolimus vs. cyclosporine does not significantly modify the risk of either de novo tumors or PTLD. However, in the absence of induction therapy, the choice of tacrolimus vs. cyclosporine appeared to modify the risk of de novo tumors and PTLD. The nonsignificant difference in post-transplant malignancy risk by tacrolimus vs. cyclosporine for patients receiving induction therapy may suggest that the strong immunosuppressive effect of induction may override differences by maintenance drugs that are observed without induction therapy. Although certain groups of patients (e.g. pediatric age group) had higher likelihood of receiving induction therapy, our analyses are not influenced by these differences, as the multivariate Cox models use adjusted comparisons for patients with the same characteristics.
In good agreement with previous studies (22) (23) (24) , we detected significant associations of increased recipient age with an elevated risk of post-transplant de novo tumors, and younger recipient age with higher risk of PTLD.
Moreover, our study showed that other demographic factors, such as male gender, White race, and non-Hispanic ethnicity, were also associated with post-transplant malignancies. The presence of diabetes appeared to reduce the tendency to develop de novo tumors. The reason for this finding is unknown.
Future SRTR studies will assess the risk of specific malignancy sites and associations with other immunosuppressive agents. Other informative studies will investigate the risk of post-transplant malignancies among transplant recipients of other organs. For instance, we plan to use the SRTR database to investigate the association between the above-mentioned immunosuppressive therapies and posttransplant malignancies among liver transplant recipients. Previous studies have suggested that recipients of an organ containing a large number of lymphocytic lineage cells that may be infected with EBV may be at greatest risk for developing PTLD (12, 25) . The SRTR database provides an excellent source to reinvestigate these issues to better estimate risks and modifiable factors with the goal of decreasing the number of malignancies among solid organ transplant recipients.
